1Madaras-Kelly KJ, Ostergaard BE, Horde LB, et al. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model[J].Antimicrob Agents Chemother, 1996, 40(3):627.
2Odenholt I, Lowdin E, Cars O. Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens[J]. Antimicrob Agents Chemother, 2001,45(1): 23.
3Mingeot-Leclereq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: aetivity and resistance[J]. Antimicrob Agents Chemother,1999,43(4) :727.
4Kollef M H, Sherman G, Word S, et al. Inadequate antimicrobial treatment of infetions: A risk factor for hospital mortality among critically ill patients. CHEST, 1999, 115: 462-472.
5WHO scientific working group on monitoring and management of bacterial resistant to antimicrobial agents. Geneva: WHO, 1994.
6Vollaard E J, Clasener H A. Colonization resistance[J]. Antimicrob Agents Chemother, 1994, 38(3): 409-414.
7Rolando N, Howard J P, Path FRC, et al. Bacterial and fungal infection in acute liver failure[J]. Sem Liv Dis, 1996, 16: 389-402.
8Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat[J]. Clin Microbiol Rev, 2001, 14: 933-951.
9Fuller R. Probiotics in human medicine[J]. Gut, 1991, 32: 439-442.
10Gibson G R, Roberfroid M B. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics[J]. J Nutr, 1995, 125(6): 1401-1412.
